Conferences

Timely clinical updates, expert perspectives, and key data from major oncology conferences, focusing on emerging evidence and treatment advancements across tumor types.

ASCO

View All

Experts Dr. Rahul Gosain, Dr. Rohit Gosain, Dr. Brian Rini, and Dr. Thomas Powles discuss 6 clinical trials on treatment options for genitourinary cancers.

ASCO

07/15/2026

6 Trials Impacting Treatment Options for Genitourinary Cancers

Thomas Powles, MD, MBBS, MRCPBrian Rini, MD, FASCORahul Gosain, MD, MBARohit Gosain, MD

Group of three medical professionals, including Dr. Hope Rugo, discussing breast cancer updates from ASCO 2026.

ASCO

07/13/2026

7 Key Breast Cancer Updates From ASCO 2026

Hope Rugo, MD, FASCORahul Gosain, MD, MBARohit Gosain, MD

Dr. Neena Vijayvergia, Dr. Rahul Gosain, and Dr. Rohit Gosain discussing key gastrointestinal trials at ASCO 2026 for clinical practice.

ASCO

07/02/2026

ASCO 2026: Key GI Trials Shaping Clinical Practice

Neena Vijayvergia, MDRahul Gosain, MD, MBARohit Gosain, MD

Dr. Joshua Brody, MD, in front of New York City skyline, discussing Liso-Cel treatment for relapsed DLBCL patients.

ASCO

07/02/2026

Liso-Cel in Relapsed DLBCL: Patient Selection, Outcomes, and Referral Strategies

Joshua Brody, MD

Image featuring Dr. Rahul Gosain, Dr. Rohit Gosain, and Dr. Isabel Preeshagul discussing NSCLC presentations at ASCO 2026 with New York City skyline in background.

ASCO

06/30/2026

4 Major NSCLC Presentations From ASCO 2026

Isabel Preeshagul, DO, MBSRahul Gosain, MD, MBARohit Gosain, MD

Presentation slide showing SARC041 study on CDK4/6 inhibition as a treatment for dedifferentiated liposarcoma with modern cityscape background.

ASCO

06/29/2026

SARC041: Establishing CDK4/6 Inhibition as a New Treatment Option in Dedifferentiated Liposarcoma

Samantha Armstrong, MD

Two medical professionals, Sawyer Bawek and Agrima Mian, discuss lymphoma data at ASCO 2026, with a city skyline background.

ASCO

06/26/2026

ASCO 2026: Key Lymphoma Data From the frontMIND and SUNMO Trials

Sawyer Bawek, DOAgrima Mian, MD

Two medical professionals, a woman and a man, stand in front of a city skyline with a banner reading 'Expanding Precision Therapy in Lung Cancer' for OncUpdates.

ASCO

06/26/2026

The Growing Role of Precision Medicine Across Lung Cancers

Stephen Liu, MDArthi Sridhar, MD

Two female medical professionals, Carolina Bernabe Ramirez and Cathy Eng, MD, FACP, FASCO, standing outdoors in front of a cityscape with a modern building, discussing pancreatic cancer research.

ASCO

06/25/2026

EPISODE-III and RASolute 302 Data From ASCO 2026

Carolina Bernabe Ramirez, MDCathy Eng, MD, FACP, FASCO

Dr. Brendan Guercio and Dr. Tian Zhang discuss perioperative strategies for high-risk localized prostate cancer at ASCO 2026.

ASCO

06/25/2026

Practice-Changing Updates for Prostate Cancer From ASCO 2026

Brendan Guercio, MDTian Zhang, MD, MHS

Dr. Samantha Armstrong, Dr. Rahul Gosain, Dr. Rohit Gosain, and Dr. Ari Rosenberg discuss key ASCO 2026 studies on head and neck cancer and sarcoma.

ASCO

06/24/2026

Key Studies in Head and Neck Cancer and Sarcoma From ASCO 2026

Samantha Armstrong, MDAri Rosenberg, MDRahul Gosain, MD, MBARohit Gosain, MD

Two medical professionals, a male and a female, smiling in front of a cityscape with a fountain, representing networking and mentorship in oncology.

ASCO

06/23/2026

ASCO Benefits for Trainees: Networking, Mentorship, and Career Growth

Sawyer Bawek, DOAgrima Mian, MD

Dr. Michael Serzan and Dr. Sumanta Pal discuss adjuvant immunotherapy in renal cell carcinoma at OncUpdates, with a city skyline and Ferris wheel in the background.

ASCO

06/22/2026

Adjuvant Immunotherapy in RCC: Insights From RAMPART

Sumanta Pal, MD, FASCOMichael Serzan, MD

Two female doctors, Arth Sridhar and Narjust Florez, smiling in front of a city skyline, discussing NSCLC trial updates for HARMONi-6 and LIBRETTO-432.

ASCO

06/22/2026

HARMONi-6 and LIBRETTO-432: Major Trial Updates for NSCLC Subtypes

Arthi Sridhar, MDNarjust Florez, MD, FASCO

Two medical professionals discussing Talquetamab monitoring and management strategies in an urban park setting.

ASCO

06/20/2026

Talquetamab Side Effects: Management and Counseling Strategies

Sawyer Bawek, DOHamza Hashmi, MD

City street scene with theater marquee and skyscrapers, highlighting recent advances in GU cancers from ASCO 2026.

ASCO

06/19/2026

Practice-Changing Shifts in GU Cancers From ASCO 2026

Manas Pustake, MD

Dr. Brian Wolpin and colleagues discuss groundbreaking data for Daraxonrasib in mPDAC from the Phase 3 RASolute 302 Trial.

ASCO

06/18/2026

Phase 3 RASolute 302 Trial: Groundbreaking Data for Daraxonrasib in mPDAC

Brian Wolpin MD MPHRahul Gosain, MD, MBARohit Gosain, MD

Two medical professionals, a young woman and an older woman, standing in front of a cityscape with a river, discussing evolving hepatocellular carcinoma treatments.

ASCO

06/18/2026

Evolving HCC Treatment: Combining Immunotherapy and TACE

Antonella Cammarota, PhDLorenza Rimassa, MD

Cityscape with river and skyscrapers, highlighting new cancer treatment developments in head and neck cancer research.

ASCO

06/17/2026

From Resistance to Response: Amivantamab Opens a New Chapter in Head and Neck Cancer

Coral Olazagasti, MD

Two medical professionals, Sawyer Bawek and Hamza Hashmi, discuss Teclistamab in earlier treatment lines for multiple myeloma with a city skyline background.

ASCO

06/17/2026

MajesTEC-9 Data and Teclistamab in Earlier Treatment Lines for Multiple Myeloma

Sawyer Bawek, DOHamza Hashmi, MD

City skyline with water and text about GU experts on bladder, kidney, and prostate cancer trials.

ASCO

06/17/2026

GU Experts Weigh In on Trials That Could Redefine Bladder, Kidney, and Prostate Cancer Care

Andre Kydd, MD, PhD

Two medical professionals, Sawyer Bawek DO and Hamza Hashmi MD, discuss the evolution of CAR T-cell therapy against a cityscape background.

ASCO

06/16/2026

The Growing Role of CAR T-Cell Therapies in Multiple Myeloma

Sawyer Bawek, DOHamza Hashmi, MD

Image showing the ASCO 2026 conference banner with the study title on a city skyline background, highlighting advancements in multiple myeloma treatment.

ASCO

06/16/2026

ASCO 2026: Mezigdomide Plus Kd Doubles PFS in Heavily Pretreated Multiple Myeloma in SUCCESSOR-2

Sawyer Bawek, DO

Aerial view of New York City skyline with river and park, highlighting advancements in pancreatic cancer treatment.

ASCO

06/15/2026

Daraxonrasib Delivers Game-Changing Survival Benefit in Previously Treated PDAC

Sunnie Kim, MD

ASCO

06/15/2026

RASolute 302: Evaluating the Side Effect Profile of Daraxonrasib

Shiraj Sen, MD, PhDRaji Shameem, MD

Visual representation of integrating circulating tumor DNA (ctDNA) into muscle-invasive bladder cancer treatment strategies, with a city skyline background.

ASCO

06/14/2026

Integrating ctDNA Into Muscle-Invasive Bladder Cancer Treatment

Miles Hsu, MD

Insights from ASCO 2026 on antibody-drug conjugates reshaping metastatic triple-negative breast cancer treatment.

ASCO

06/14/2026

Insights from ASCO 2026: Antibody–Drug Conjugates Continue to Reshape Metastatic Triple-Negative Breast Cancer

Stephanie Haddad, DO

HPV-negative head and neck squamous cell carcinoma research, treatment strategies, and clinical insights by Nicole Dalal, MD, and Fangdi Sun, MD.

ASCO

06/13/2026

Emerging Data on Amivantamab and Other Anti-EGFR Bispecifics in Head and Neck Cancer

Nicole Dalal, MDFangdi Sun, MD

Healthcare professionals Alexis LeVee, MD, and Hope Rugo, MD, FASCO, discuss community perspectives on ADCs and novel agents in triple-negative breast cancer (TNBC).

ASCO

06/12/2026

Breast Oncologists Discuss the Current Paradigm and Future Advancements for ADCs in TNBC

Alexis Levee, MDHope Rugo, MD, FASCO

Molecular profiling and treatment sequencing in HR-positive breast cancer with Dr. Ya Haddy Sallah and Dr. Jimmitti Teysir.

ASCO

06/12/2026

How Molecular Profiling Guides Targeted Therapy Options in HR–Positive Breast Cancer

Jimmitti Teysir, MDYa Haddy Sallah, MD, MPH

Overview of GLP-1 receptor agonists and their role in breast cancer treatment, featuring insights from Cleveland Clinic expert Jasmin Hundal, MD, MS, MPH.

ASCO

06/11/2026

GLP-1 Receptor Agonists in Breast Cancer: Moving Beyond Weight Loss Toward Cancer Prevention and Survivorship

Jasmin Hundal, MD

Experts discuss innovative treatment strategies for metastatic ER-positive breast cancer against a city skyline at sunset. Focus on oncology, breast cancer, and advanced therapies.

ASCO

06/11/2026

How To Approach Endocrine Therapies for Metastatic Breast Cancer in the Adjuvant CDK4/6 Inhibitor Era

Jasmin Hundal, MDDionisia Quiroga, DO, PhD

Medical professionals discussing considerations and clinical trials for early-stage breast cancer treatment.

ASCO

06/10/2026

Oncologists Consider Potential Roles of ADCs in Early-Stage Breast Cancer Treatment

Alexis Levee, MDHope Rugo, MD, FASCO

ASCO 2026 presentation on Giredestrant for ER+/HER2- metastatic breast cancer at Roswell Park Cancer Center.

ASCO

06/10/2026

ASCO 2026: Evaluating Giredestrant in First-Line ER+/HER2- Metastatic Breast Cancer

Vaishali Deenadayalan, MD

Two doctors discussing zanidatamab-based treatment options for HER2-positive gastric cancer against a city skyline background.

ASCO

06/10/2026

HERIZON-GEA-01 Updates and Sequencing HER2-Directed Treatments in Gastric Cancer

Geoffrey Ku, MDSteven Maron, MD, MSc

Two medical professionals, Joseph McCollom, DO, and Rachna Shroff, MD, MS, FASCO, discuss the latest updates on upper gastrointestinal cancer care at the Matterhorn conference.

ASCO

06/09/2026

GI Oncologists Discuss MATTERHORN Updates and Challenging HCC Subgroups

Joseph McCollom, DORachna Shroff, MD, MS, FASCO

Experts Alexis LeVee, MD, and Hope Rugo, MD, discuss optimizing ADC selection for metastatic triple-negative breast cancer treatment.

ASCO

06/09/2026

The Current Paradigm for Selecting and Sequencing ADCs in Metastatic TNBC

Alexis Levee, MDHope Rugo, MD, FASCO

Two medical professionals, Deepak Vadehra, DO and Charbel Matar, MD, discussing RASolution 302 and targeted therapy for gastrointestinal cancers in an urban setting.

ASCO

06/09/2026

Experts Review Groundbreaking Data From RASolute 302 and Its Impact on GI Oncology

Charbel Matar, MDDeepak Vadehra, DO

ASCO

06/09/2026

Key ASCO 2026 Updates in NSCLC and SCLC

Chinmay Jani, MDTessa Lavorgna, MD

Two medical professionals, Dr. Rohit Gosain and Dr. Danai Dima, discuss CAR-T therapy for multiple myeloma in an urban cityscape background.

ASCO

06/08/2026

How Community Oncologists Can Optimize CAR T-Cell Therapy for Patients With Multiple Myeloma

Danai Dima, MDRohit Gosain, MD

Expert discussion on perioperative chemoimmunotherapy for upper gastrointestinal cancer, highlighting recent advances and treatment strategies.

ASCO

06/08/2026

Doctors React to the New Treatment Landscape for Gastric and Gastroesophageal Junction Cancers

Charbel Matar, MDRaji Shameem, MD

Experts discuss personalized adjuvant CDK4/6 inhibitor therapy for breast cancer in a professional conference setting.

ASCO

06/08/2026

How to Select a CDK4/6 Inhibitor in Early or Metastatic Breast Cancer

Giuseppe Curigliano, MD, PhDArya Mariam Roy, MD

Two female doctors, Sarah Premji, MD, and Komal Jhaveri, MD, FACP, discussing biomarker testing for HR-positive metastatic breast cancer against a city skyline background.

ASCO

06/07/2026

Biomarker Testing and Targeted Therapy Advancements in Metastatic Breast Cancer

Komal Jhaveri, MD, FACPSarah Premji, MD

Zanidatamab emerging as a potential new standard of care in oncology, featuring Dr. Shruti Patel and Dr. Tanios Bekaii-Saab discussing innovative cancer treatment options.

ASCO

06/07/2026

Transformational Data From HERIZON-GEA-01 and RASolute 302 for GI Malignances

Tanios Bekaii-Saab, MDShruti Patel, MD

Aerial view of a city skyline with a waterfront, highlighting the latest insights from ASCO 2026 on evolving treatment strategies for gastrointestinal cancers.

ASCO

06/07/2026

Insights From ASCO 2026: Evolving Treatment Strategies in Gastrointestinal Malignancies

Aslihan Yerlikaya, MD

OncUpdates episode featuring discussions on bringing Mezidomide into clinical practice, focusing on efficacy, safety, and implications for oncology treatment.

ASCO

06/07/2026

Bringing Mezigdomide Into Practice: Efficacy, Safety, and Clinical Implications

Paul G. Richardson, MDRahul Gosain, MD, MBA

Expert discussion on Mezidomide's mechanism of action and early clinical development, featuring Rahul Gosain and Paul Richardson.

ASCO

06/07/2026

Understanding Mezigdomide: Mechanism of Action and Early Clinical Development

Paul G. Richardson, MDRahul Gosain, MD, MBA

Experts Christine Garcia, MD, MPH, and Rami Manoachakian, MD, discuss innovative small cell lung cancer treatments in a city skyline setting.

ASCO

06/06/2026

Oncologists Highlight Tarlatamab and Other Advancements in SCLC

Chirstine Garcia, MD, MPHRami Manochakian, MD

Dr. Elias Chandran and Dr. Andrea Apolo discuss the latest developments in bladder cancer care, highlighting EV-Pembrolizumab's role in redefining treatment strategies.

ASCO

06/06/2026

The Impact of EV Trials Across Bladder Cancer Populations

Andrea Apolo, MDElias Chandran, MBBS, FRACP

Clinical trial image showing Broke Kania, DO, discussing the Talaporo-3 study on cancer treatment with Talazoparib and Enzalutamide for HRR-mutated mCSPC.

ASCO

06/06/2026

TALAPRO-3: A Major rPFS Win in HRR-Mutated mCSPC, But Which Patients Benefit Most?

Brooke Kania, DO

Experts Dr. Rohit Gosain and Dr. Samer Al Hadidi discuss follow-up data on CAR T cell therapy safety and effectiveness in high-risk multiple myeloma patients.

ASCO

06/05/2026

ASCO 2026 Follow-Up Data Support CAR T Safety and Activity in High-Risk Multiple Myeloma

Samer Al Hadidi, MDRohit Gosain, MD

Experts discuss the significance of adjuvant Durvalumab monotherapy in rapid cancer treatment responses.

ASCO

06/05/2026

MATTERHORN Analysis Upholds Value of Adjuvant Durvalumab Maintenance Period

Samuel Cytryn, MDRutika Mehta, MD, MB, MPH

Overview of the Episode III clinical trial showing aspirin's lack of DFS benefit in stage III colorectal cancer, with a cityscape background.

ASCO

06/05/2026

EPISODE-III Trial: Adjuvant Aspirin Shows No DFS Benefit in Stage III CRC

Young Rho, MD

Overview of six key breast cancer clinical trials presented at ASCO 2026, highlighting advancements in breast cancer treatment and research.

ASCO

06/04/2026

Six Practice-Informing Breast Cancer Trials From ASCO 2026

Nerea Lopetegui-Lia, MD

Overview of EV-302 update on enfortumab vedotin and pembrolizumab improving survival in metastatic urothelial cancer patients.

ASCO

06/03/2026

EV-302 Update: Enfortumab Vedotin Plus Pembrolizumab Maintains Survival Benefit at 3.5 Years in Metastatic Urothelial Cancer

Saad Atiq, MD

$Experts discuss new treatment strategies for relapsed and refractory multiple myeloma, focusing on rapid response and expanding therapeutic options.$

ASCO

06/03/2026

Rapid Reactions: Expanding Treatment Options in Relapsed/Refractory Multiple Myeloma

Paul G. Richardson, MDRahul Gosain, MD, MBA

Overview of thoracic oncology highlights at ASCO 2026, focusing on lung cancer research and treatment updates for oncologists and medical professionals.

ASCO

05/28/2026

What to Watch at ASCO 2026: A Thoracic Oncologist’s Guide to the Lung Cancer Program

Dan Morgenstern, MDChinmay Jani, MDGilberto Lopes, MD

Modern metallic sculpture in an urban setting with skyscrapers, promoting the ASCO 2026 gastrointestinal cancer conference and research updates.

ASCO

05/15/2026

ASCO 2026: Gastrointestinal Abstracts to Watch

Raji Shameem, MD

Innovative cancer research expert speaking at OncUpdates conference, discussing latest advancements in oncology and personalized treatment strategies, in a professional setting.

ASCO

09/09/2025

Preferred Sequencing of Treatment for Neuroendocrine Tumors

Deepak Vadehra, DOTanios Bekaii-Saab, MD

Microscopic view of cancer cells with surrounding blood cells and immune response, illustrating recent oncological updates and advancements in cancer research.

ASCO

08/26/2025

Updates in Breast Cancer From ASCO 2025

Zunairah Shah, MD

Lung anatomy with highlighted bronchi and surrounding structures in a digital medical illustration.

ASCO

07/28/2025

Thoracic Oncology in 2025: Evolving Standards and Practice-Changing Data From ASCO

Kriti Ahuja, MD

A woman speaking at an oncology conference, wearing a black leather jacket and a red heart-shaped brooch, with a backdrop displaying "Advancements in Oncology" and "Onc Brothers.".

ASCO

07/25/2025

Innovación dirigida: datopotamab deruxtecan en el tratamiento del cáncer de pulmón no microcítico avanzado

Coral Olazagasti, MDNarjust Florez, MD, FASCO

OncUpdates breast cancer clinical trials expert panel discussing key advancements in breast cancer treatment and innovative therapies. Featuring Dr. Erika Hamilton, Dr. Rohit Gosain, and Dr. Rahul Gosain.

ASCO

07/22/2025

5 Key Breast Cancer Clinical Trials Shaping Treatment

Erika Hamilton, MD, FASCO

GU Malignancy Recap from 2025 ASCO, oncology, cancer research, medical conference, Dr. Tian Zhang, Dr. Rohit Gosain, Dr. Rahul Gosain, oncotherapy, cancer treatment advances, oncology news, clinical updates, oncologists, cancer management.

ASCO

07/22/2025

GU Malignancy Recap from 2025 ASCO

Tian Zhang, MD, MHS

Healthcare professional giving a presentation at an oncology conference, promoting advancements in cancer research and treatment, with a focus on future practices and innovative oncology breakthroughs.

ASCO

07/02/2025

Datopotamab Deruxtecan in NSCLC: A Closer Look at TROP2-Targeted Therapy

Coral Olazagasti, MDNarjust Florez, MD, FASCO

OncUpdates conference panel discussion featuring medical professionals discussing oncology advancements and cancer treatment strategies at a professional medical event.

ASCO

07/02/2025

Breakthroughs in Bladder, Prostate, and Kidney Cancer: What Oncologists Need to Know From ASCO 2025

Saad Atiq, MD

Microcancer cells in human bladder illustrating cancer biology and urology research.

ASCO

06/30/2025

Durvalumab Enters the Perioperative Landscape in Muscle-Invasive Bladder Cancer: Reflections from the NIAGARA Trial and ASCO 2025 Updates

Charbel Matar, MD

Five major colorectal and gastrointestinal cancer abstracts from 2025 ASCO conference, analyzed by oncologists with insights on latest research and breakthroughs in cancer treatment.

ASCO

06/27/2025

Five Major Colorectal and GI Cancer Abstracts From 2025 ASCO

Rahul Gosain, MD, MBARohit Gosain, MDCathy Eng, MD, FACP, FASCO

Innovative cancer research discussion at OncUpdates featuring leading oncologists sharing insights on recent advances in oncology treatments and therapies.

ASCO

06/11/2025

Clinical Impact of DESTINY-Breast09 in HER2+ Breast Cancer Management

Arya Mariam Roy, MDHope Rugo, MD, FASCO

Innovative oncology conference with experts discussing advancements in cancer treatment and research in a modern, well-lit venue.

ASCO

06/11/2025

Small Cell Lung Cancer Takes Center Stage at ASCO 2025

Eric Singhi, MDSandip Patel, MD, FASCO

Advances in oncology, cancer research, and breakthrough treatments discussed at an oncology conference with medical professionals.

ASCO

06/11/2025

Strategic Timing for Multidisciplinary Care in Breast Cancer

Jasmin Hundal, MDMatthew Kurian, MD

Innovative oncology discussion at OncUpdates conference focused on advancements in cancer treatment and care. Two experts sharing insights on future oncology practices at the event.

ASCO

06/11/2025

ASCO 2025: Key Clinical Trials in Resectable NSCLC

Eric Singhi, MDMitchell Alexander Parma, MD

Oncoupdates, oncology conference, medical professionals, cancer research, healthcare presentation, cancer awareness, medical event, oncology advancements, professional networking, cancer treatment innovation.

ASCO

06/11/2025

Tailoring Treatment for Patients With EGFR-Positive NSCLC

Chinmay Jani, MDCoral Olazagasti, MD

High-tech illustration of a human prostate gland with medical visualization elements, symbolizing advanced prostate cancer research and treatment options.

ASCO

06/11/2025

New Questions in Muscle-Invasive Bladder Cancer After the NIAGARA Trial

Albert Jang, MDMichael Serzan, MD

Advances in oncology research and treatment discussed at OncUpdates, featuring medical professionals sharing insights on cancer therapies and breakthroughs, highlighting the latest in cancer care.

ASCO

06/11/2025

Highlights From the AMPLITUDE Study at ASCO 2025

Albert Jang, MDMichael Serzan, MD

Alcohol-reinforcement-removal-urinary-kidney-cancer-treatment-therapy-illustration.

ASCO

06/11/2025

Updated CheckMate 214 Results Support Ipi-Nivo for Favorable-Risk Kidney Cancer

Albert Jang, MDMichael Serzan, MD

Data for tomorrow’s oncology practice and research, oncological innovations, cancer treatment advancements, and cancer research updates at OncUpdates.

ASCO

06/11/2025

MATTERHORN Trial: Promising Results and Unanswered Questions

Deepak Vadehra, DOSupriya Peshin, MD

Innovative oncology research discussion at OncUpdates conference, focusing on advancements in cancer treatment, personalized medicine, and new therapies in oncology.

ASCO

06/11/2025

Diverse Bispecific Strategies Emerging Across GI Cancers

Shruti Patel, MDUdhayvir Singh Grewal, MD

Two women engaged in a discussion on stage at the ASCO 2025 oncology conference, with a backdrop of plants and modern decor.

ASCO

06/11/2025

Advancements in Oncology at ASCO 2025: Breast Cancer Highlights

Tanmayi Pai, MD

High-quality healthcare professional woman speaking at oncology conference, discussing cancer treatment updates, in a comfortable, modern setting with natural lighting and stylish decor.

ASCO

06/10/2025

Key Takeaways From ASCO 2025 for Hormone-Receptor+ Metastatic Breast Cancer

Komal Jhaveri, MD, FACPMatthew Kurian, MD

Leading female medical expert speaking at a conference on oncology advances, holding a microphone, surrounded by large green plants, emphasizing innovative cancer research and treatment updates.

ASCO

06/10/2025

Integrating Metastatic Triple-Negative Breast Cancer NCCN Guidelines Into Clinical Practice

Arya Mariam Roy, MDHope Rugo, MD, FASCO

ASCO

06/10/2025

ASCENT-04 Trial: First-Line Sacituzumab Govitecan Plus Pembrolizumab Improves PFS in PD-L1+ TNBC

Arya Mariam Roy, MDHope Rugo, MD, FASCO

Innovative oncology conference speakers discussing advancements in cancer research at OncUpdates event.

ASCO

06/10/2025

Lurbinectedin Offers Significant Survival Benefit for Patients With Extensive-Stage SCLC

Eric Singhi, MDSandip Patel, MD, FASCO

Bald man in suit and tie speaking into a microphone at a conference, sitting on a wicker armchair surrounded by plants and modern decor, representing oncology professional at a medical event.

ASCO

06/10/2025

Second-Line Treatment Sequencing in Metastatic RCC

Enrique Grande, MD, PhD, MSCKaran Jatwani, MD

Answer:.

ASCO

06/10/2025

NIAGARA Trial: A New Standard of Care in MIBC

Petros Grivas, MD, PhDMichael Serzan, MD

Cutting-edge oncology conference interview with medical professionals discussing advancements in cancer research and treatment strategies for improved patient outcomes.

ASCO

06/10/2025

The Future of Sacituzumab Govitecan in Metastatic Urothelial Cancer

Michael Serzan, MDPetros Grivas, MD, PhD

Innovative cancer treatment discussion at Oncology conference focusing on advancements in oncology research, therapies, and patient care.

ASCO

06/10/2025

Interpreting the Broad Cabozantinib Label for NETs

Neena Vijayvergia, MDShruti Patel, MD

Expert woman in black blazer speaking at a medical conference, discussing oncology topics and cancer research on stage.

ASCO

06/10/2025

Considering Frontline PRRT in NETs

Neena Vijayvergia, MDShruti Patel, MD

Discussion panel at a medical conference with professionals in a modern cityscape setting, focused on oncology updates and research advancements.

ASCO

06/10/2025

Shifting Paradigms in Lung Cancer Care: Insights From ASCO 2025

Maria A. Velez, MD, MS

Expert medical professionals discuss cancer treatment advances at an oncology conference, emphasizing personalized medicine and innovative research in cancer care.

ASCO

06/10/2025

Latest GI Cancer Trends From ASCO 2025: Molecular Testing, IO Strategies & Targeted Therapy

Seyi Abidoye, MBBSLisa Liu, MD

Enhanced visualization of the human digestive system highlighting the stomach and intestines for medical and anatomical research.

ASCO

06/03/2025

ASCO 2025 Highlights: Breakthroughs in GI Oncology From BREAKWATER, MATTERHORN, ATOMIC & CHALLENGE

Sawyer Bawek, DO

ASCO GI

View All

Advanced research on gastrointestinal cancers highlighting biomarker-driven therapies for CRC and NETs, featuring expert insights from Deepak Vadehra, DO, at Roswell Park Comprehensive Cancer Center.

ASCO GI

02/12/2026

Gastrointestinal Cancers: Biomarker-Driven Advances in CRC and NETs

Deepak Vadehra, DO

Improved, SEO-friendly responses:.

ASCO GI

02/05/2026

The Uncertain Role of ctDNA in Colorectal Cancers

Lauren Laderman, MDUdhayvir Singh Grewal, MD

Early-Onset Gastrointestinal Cancers research highlights genetics, survivorship, and care models for young patients, featuring MDs Youssef Bouferraa and Shruti Patel in an oncology conference setting.

ASCO GI

02/04/2026

Updating Care Models for Patients With Early-Onset GI Cancer

Youssef Bouferraa, MDShruti Patel, MD

1. Expert discussion on preventing chemotherapy toxicity and the importance of universal DPYD testing for cancer patients.

ASCO GI

02/03/2026

FDA Update Reflects Need for Genetic Testing Prior to Capecitabine

Karen MerrittVimal Scott Kapoor, MD, BSc, MSc

NGS and targeted therapies for advanced gastroesophageal cancer, featuring specialists Ajinkya Buradkar, MD and Meghana Singh, MD, with a cityscape background and professional medical presentation.

ASCO GI

01/29/2026

Biomarker Testing and Key Subgroups in Gastric and GEJ Cancer

Ajinkya Buradkar, MDMeghana Singh, MD

Metastatic neuroendocrine tumor research featuring scientists Udhayvir Grewal and Neena Vijayvergia with a city skyline and bridge background, highlighting innovative neuroendocrine tumor imaging tools.

ASCO GI

01/27/2026

64Cu-SARTATE Improves Tumor Detection in GEP-NETs

Udhayvir Singh Grewal, MDNeena Vijayvergia, MD

Zolbetuximab immunotherapy research on upper GI cancers with Dr. Shruti Patel and Dr. Timothy Brown on OncUpdates platform, highlighting innovative cancer treatment developments and future of targeted therapies.

ASCO GI

01/26/2026

The Future of Zolbetuximab in Upper GI Cancers

Timothy Brown, MD, MSCEShruti Patel, MD

PARP inhibition and immunotherapy in gastrointestinal malignancies, featuring experts Kriti Ahuja, MBBS, and Dr. Dina Ioffe, exploring biological rationale for advanced cancer treatment strategies.

ASCO GI

01/24/2026

ASCO GI 2026 Highlights: PARP Inhibitors Plus Immunotherapy

Kriti Ahuja, MDDina Ioffe, MD

CT22-01-2023 - Medical professional analyzing upper gastrointestinal cancer research updates at Roswell Park, highlighting practice-changing advances in diagnosis and treatment.

ASCO GI

01/23/2026

Practice-Changing Updates in Upper Gastrointestinal Cancers From ASCO GI 2026

Vaishali Deenadayalan, MD

HER2-targeted therapy in upper GI cancers, innovative strategies for treatment and research advancements by oncologists Meghana Singh and Richard Dunne.

ASCO GI

01/23/2026

HER2-Targeted Regimens Transform Frontline Management of Upper GI Cancers

Richard Dunne, MD, MSMeghana Singh, MD

ASCO GI

01/22/2026

Expert Perspectives on the BREAKWATER Trial in Metastatic Colorectal Cancer

Daniel Tuerff, MDNicholas Hornstein, MD, PhD

1. Expert panelists Dr. Rohit Gosain, Dr. Rachna Shroff, and Dr. Rahul Gosain discuss key insights on gastrointestinal cancers at the 2026 ASCO Gastrointestinal Cancers Symposium.

ASCO GI

01/22/2026

4 Key Abstracts from the 2026 ASCO Gastrointestinal Cancers Symposium

Rachna Shroff, MD, MS, FASCORahul Gosain, MD, MBARohit Gosain, MD

CBADet, MSS Colorectal Cancer, and Emerging Practice-Changing Data in Oncology research and updates.

ASCO GI

01/21/2026

CABINET and STELLAR-303 Trials Inform Treatment in NETs and mCRC

Nicholas Hornstein, MD, PhDAnwaar Saeed, MD

Pancreatic cancer biomarker testing and clinical decision-making, patient-centered care seminar featuring Fiyinfolu Balogun MD PhD and Wungki Park MD MS in front of a cityscape with a bridge at sunset.

ASCO GI

01/19/2026

ASCO GI 2026: Precision Medicine Gains Momentum in Pancreatic Cancer

Fiyinfolu Balogun, MD, PhDWungki Park, MD, MS

KRAS inhibitors, targeted therapy, GI oncology, cancer treatment, molecular targeted therapy, cancer research, precision medicine, oncology advancements, clinical oncology, cancer therapy innovation.

ASCO GI

01/19/2026

Molecular Profiling Expands Treatment Options in Pancreatic and Biliary Tract Cancers

Dina Ioffe, MDShubham Pant, MD, MBBS

ASCO GU

View All

Advanced medical professionals discussing bladder, kidney, and prostate cancer updates at ASCO GU 2026 conference.

ASCO GU

03/25/2026

Bladder, Kidney, and Prostate Cancer Highlights From ASCO GU 2026

Petros Grivas, MD, PhDRahul Gosain, MD, MBARohit Gosain, MD

Bladder, prostate, and kidney cancer updates from ASCO GU 2026, featuring medical professionals discussing recent advancements in cancer treatment and research.

ASCO GU

03/20/2026

ASCO GU 2026: Key Updates in Bladder, Prostate, and Kidney Cancer

Charbel Matar, MD

Advanced renal cell carcinoma research on HIF-2α inhibition featuring Dr. Michael Serzan and Dr. Toni Choueiri, with a cityscape background, highlighting innovative cancer treatment developments.

ASCO GU

03/16/2026

Positive Trials for Belzutifan in Earlier Treatment Lines for RCC

Michael Serzan, MDToni Choueiri, MD

EV Plus Pembrolizumab and Systemic Therapy Advances in GU Oncology - OncUpdates.

ASCO GU

03/16/2026

Community Takeaways From ASCO GU 2026

Regina Barragan-Carrillo, MDRaji Shameem, MD

Advanced molecular testing and targeted therapies for prostate cancer research and treatment.

ASCO GU

03/16/2026

ASCO GU 2026: Experts Highlight Key Updates in Prostate Cancer

Brooke Kania, DOSindhuja Kadambi, MD, MS

Postoperative radiation and personalized therapy in GU cancers, featuring two smiling female doctors against a cityscape background.

ASCO GU

03/16/2026

A Personalized Approach to Treating GU Cancers

Sophia Kamran, MDNatalie Reizine, MD

HER2-Directed Strategies in Urothelial Cancer, featuring Dr. Miles Hsu and Dr. Brendan Guercio discussing innovative treatments for bladder cancer, with a cityscape background.

ASCO GU

03/15/2026

Novel HER2–Targeting Therapies in Urothelial Cancer

Miles Hsu, MDBrendan Guercio, MD

Radiotherapy strategies in metastatic clear cell renal cell carcinoma featuring Dr. Shreyas Kalantri and Dr. Michael Serzan with a cityscape background.

ASCO GU

03/15/2026

Radiotherapy Strategies in Metastatic Clear Cell Renal Cell Carcinoma

Michael Serzan, MDShreyas Kalantri, MD

Advanced medical professionals discussing Radium-223 Plus Enzalutamide in mCRPC with bone metastases in an urban hospital setting.

ASCO GU

03/14/2026

PEACE-3 OS Data Support Radium-223 Plus Enzalutamide in Metastatic Castration-Resistant Prostate Cancer

Sindhuja Kadambi, MD, MSKarine Tawagi, MD

Researchers Brendan Guercio, MD, and Andrea Apolo, MD, discuss circulating tumor DNA for guiding muscle-invasive bladder cancer treatment, with a cityscape background.

ASCO GU

03/13/2026

Circulating Tumor DNA to Guide Treatment in Muscle-Invasive Bladder Cancer

Brendan Guercio, MDAndrea Apolo, MD

ASCO GU 2026 conference banner highlighting novel therapies transforming genitourinary oncology, featuring the Golden Gate Bridge in San Francisco.

ASCO GU

03/13/2026

ASCO GU 2026: Novel Therapies Transform Genitourinary Oncology

Manas Pustake, MD

Enhanced cancer treatment research featuring Dr. Nicholas Simon and Dr. Sumanta Pal discussing Cabozantinib and novel doublets in advanced renal cell carcinoma.

ASCO GU

03/12/2026

Cabozantinib and Novel Doublets in Advanced RCC

Nicholas Simon, MDSumanta Pal, MD, FASCO

Advanced medical professionals discussing metastatic renal cell carcinoma treatment strategies in a modern urban setting.

ASCO GU

03/12/2026

First-Line Treatment Strategies in Metastatic Renal Cell Carcinoma

Andre Kydd, MD, PhDNicholas Simon, MD

PARP inhibitor combination therapy in metastatic prostate cancer, featuring Jeffrey Zhong, MD, and Karan Jatwani, MD, with a cityscape background.

ASCO GU

03/11/2026

PARP Inhibitor Combination Therapy in Metastatic Prostate Cancer

Karan Jatwani, MDJeffrey Zhong, MD

EV Plus Pembro improves outcomes in muscle-invasive bladder cancer in KEYNOTE-B15/EV-304, featuring researchers Rohit Gosain, MD, and Rahul Gosain, MD, MBA, with a cityscape background.

ASCO GU

03/10/2026

Enfortumab Vedotin Plus Pembrolizumab Improves Outcomes in Muscle-Invasive Bladder Cancer in KEYNOTE-B15/EV-304

Rahul Gosain, MD, MBARohit Gosain, MD

Efficacy of Enfortumab Vedotin and Pembrolizumab in muscle-invasive bladder cancer treatment, featuring experts Elias Chandran and Vishesh Khanna against a cityscape background.

ASCO GU

03/09/2026

Enfortumab Vedotin-Pembrolizumab’s Role in Muscle-Invasive Bladder Cancer Treatment

Elias Chandran, MBBS, FRACPVishesh Khanna, MD

Evolving treatment strategies in bladder cancer research presented by OncUpdates, featuring medical professionals discussing innovative therapies and recent advancements in bladder cancer management.

ASCO GU

03/09/2026

Insights from ASCO GU 2026: Evolving Treatment Strategies in Bladder Cancer

Zeynep Irem Ozay, MD

Enhanced immunotherapy plus BCG treatment for high-risk non-muscle invasive bladder cancer; two doctors in formal attire with cityscape background.

ASCO GU

03/08/2026

Immunotherapy Plus BCG Shows Promise in NMIBC: Insights From POTOMAC and CREST

Ashish M. Kamat, MD, MBBS, FACSVishesh Khanna, MD

Advanced prostate cancer treatment research featuring Karan Jatwani, MD, and Alan Bryce, MD, with a city skyline background.

ASCO GU

03/06/2026

Capivasertib Plus Abiraterone in Metastatic Prostate Cancer

Alan Bryce, MDKaran Jatwani, MD

Evolving standards in renal cell carcinoma research and treatment, with practical insights for healthcare professionals and oncologists.

ASCO GU

03/05/2026

Evolving Standards in Renal Cell Carcinoma: Practical Insights from ASCO GU

Adriana Penate, MD

ASH

View All

An image of Dr. Jorge Cortes presenting AML and CML highlights from ASH 2025, featuring Dr. Rahul Gosain and Dr. Rohit Gosain, with a professional background related to hematology and oncology researc.

ASH

03/04/2026

AML and CML Highlights From ASH 2025

Jorge Cortes, MDRahul Gosain, MD, MBARohit Gosain, MD

Bispecifics, BTK inhibitors, and immunotherapy advances in lymphoma treatment, featuring experts Dr. Rahul Gosain, Dr. Julie Vose, and Dr. Rohit Gosain at OncUpdates conference.

ASH

02/26/2026

Bispecifics, BTK Inhibitors, and Immunotherapy Drive Lymphoma Advances

Julie Vose, MD, MBARahul Gosain, MD, MBARohit Gosain, MD

A groundbreaking presentation on AQUILA, COBRA, TecLLE, and MajesTEC-3 trials highlighting innovative signal shifts in myeloma management by leading oncology experts.

ASH

02/24/2026

AQUILA, COBRA, TecLILLE, and MajesTEC-3 Trials Signal Shifts in Myeloma Management

Ben Derman, MDRahul Gosain, MD, MBARohit Gosain, MD

Advanced visualization of immune cells and cancerous cells related to multiple myeloma, highlighting emerging treatment strategies and expert insights.

ASH

02/19/2026

Expert Insight on Emerging Strategies in Multiple Myeloma

Mehndi Dandwani, MD

Azacitidine and venetoclax combination therapy for AML, showcasing practice-changing insights from ASH 2025 presented by Jayastu Senapati and Uma Borate.

ASH

01/16/2026

Azacitidine in AML: Key Takeaways From the PARADIGM Study

Jayastu Senapati, MBBSUma Borate, MBBS

Multimodal image featuring two doctors discussing cellular therapy for multiple myeloma, with cityscape background, emphasizing oncology research, CAR T-cell therapy, bispecific antibodies, and personalized cancer care advancements.

ASH

01/16/2026

Collaboration is Key to Safely Transition Care in MM Following Cellular Therapy

Hamza Hashmi, MDShreyas Kalantri, MD

ASH

01/15/2026

Insights on CAR-NK Therapy and Hodgkin Lymphoma Updates at ASH 2025

Sam Yamshon, MDAndrew Evens, DO, MBA, MSc

1. Expert oncologists Kingsley Nnawuba and Urshila Durani discuss advancements in lymphoma treatment, including ESMO guidelines, immunotherapy, and combination therapies for improved patient outcomes.

ASH

01/13/2026

Oncologists Review Practice-Changing Lymphoma Findings From ASH 2025

Kingsley Nnawuba, MDUrshila Durani, MD, MPH

Blood sample in a test tube with laboratory report background, highlighting hematology and oncology research.

ASH

01/11/2026

Key Studies Shaping Hematology, Community Oncology at ASH 2025

Sawyer Bawek, DO

Prognostic criteria and role of Daratumumab in high-risk smoldering myeloma, featuring experts Jing Wang, MD and Anuja Abhyankar, MD, discussing recent advancements in multiple myeloma treatment.

ASH

01/08/2026

Early Intervention Strategies in High-Risk Smoldering Multiple Myeloma

Anuja V. Abhyankar, MDJing Wang, MD

Enhanced medical research on hematology and oncology at ASH 2025 conference with clinical laboratory professionals.

ASH

01/07/2026

ASH 2025 Breakthroughs: Key Studies Shaping Hematology and Community Oncology

Sawyer Bawek, DO

$1. Researchers and clinicians discuss strategies for managing lenalidomide, CD38, and multi-refractory disease in relapsed multiple myeloma treatment at OncUpdates conference.$

ASH

01/04/2026

How to Select Treatment in Relapsed Multiple Myeloma

Anuja V. Abhyankar, MDS. Vincent Rajkumar, MD

Early use of bispecific antibodies and CAR T strategies in relapsed multiple myeloma, discussed by experts Hamza Hashmi, MD, and Robert Orlowski, MD, PhD, with a cityscape background.

ASH

01/03/2026

Bispecific Antibodies and CAR T Redefine Early-Line Treatment in Multiple Myeloma

Robert Orlowski, MD, PhDHamza Hashmi, MD

Advanced AML treatment discussing FLT3 inhibitors, menin targeting, and triplet regimens with experts Abhishek Maiti, MD, and Jorge Cortes, MD, in a clinical oncology-focused presentation.

ASH

01/01/2026

Targeted Combinations Transform AML Care

Abhishek Maiti, MDJorge Cortes, MD

1. Expert oncologists discussing future trends in chronic myeloid leukemia (CML) therapy and insights from key clinical trials including ASC4, OPTIC, and ASXL1 for 2025.

ASH

12/31/2025

ASH 2025 CML Highlights: Asciminib, Ponatinib Optimization, and Treatment Sequencing

Sawyer Bawek, DOFadi Haddad, MD

Pre-transplant functional status as a predictor of autologous myeloma transplant outcomes, featuring Rahul Gosain, MD, MBA and Sawyer Bawek, DO, with a cityscape background.

ASH

12/29/2025

Pretransplant Functional Status as a Predictor of Outcomes in Multiple Myeloma

Sawyer Bawek, DORahul Gosain, MD, MBA

Bispecific antibodies and CAR T-cell therapy for emerging data in TP53-mutated AML and MDS, featuring experts Mycal Casey, DO, and Abishek Maiti, MD, at OncUpdates conference.

ASH

12/24/2025

Reviewing ASH 2025 Data for ALL and TP53-Mutated AML or MDS

Abhishek Maiti, MDMycal Casey, DO

1. Advanced blood cancer cells including leukemia, lymphoma, myeloma, and chronic lymphocytic leukemia (CLL).

ASH

12/24/2025

CLL, AML, Lymphoma, and Myeloma Updates Poised to Impact Clinical Practice

Valentina Ardila Avila, MD

1. Expert oncologists discussing treatment options for cancer, emphasizing Venetoclax-based regimens, targeted agents, and rapid molecular profiling for personalized therapy.

ASH

12/23/2025

Improving Venetoclax and Other Targeted Therapies in AML

Zachary Braunstein, MDJayastu Senapati, MBBS

Enhanced leukemia research and advancements discussed at ASH 2025, offering expert insights and future directions in hematologic cancer treatment from renowned specialists.

ASH

12/23/2025

Leukemia Advances at ASH 2025: Expert Insights and Future Directions

Niranjan Khaire, MBBS, MD, DM

Advanced personalized chemotherapy strategies for chronic lymphocytic leukemia based on ASH 2025 guidelines. Expert insights by Lauren M. Granat, DO, MS, on targeted cancer therapies.

ASH

12/22/2025

ASH 2025 Signals Shift Toward Personalized, Time-Limited Therapy in Chronic Lymphocytic Leukemia

Lauren M. Granat, DO, MS

1. Experienced medical professionals discussing Sonrotoclax in mantle cell lymphoma at ASH 2025 clinical conference.

ASH

12/20/2025

Experts Discuss Sonrotoclax and Lymphoma Trials at ASH 2025

Agrima Mian, MDSam Yamshon, MD

ASH

12/20/2025

Ibrutinib Updates in CLL From ASH 2025

Mahesh Swaminathan, MB, MSVanthana Bharthi, MD

1. Expert insights on frontline BTK inhibitors and triplet therapy for CLL at ASH 2025, featuring Mahesh Swaminathan and Bita Fakhri.

ASH

12/18/2025

Breaking Down ASH 2025 Data on Frontline Pirtobrutinib in CLL

Bita Fakhri, MD, MPHMahesh Swaminathan, MB, MS

Non-covalent BTKi efficacy post-covalent BTKi or BCL-2 therapies in cancer treatment, featuring experts Claudia Villa Celi, MD, and Daniel Ermann, MD, for oncology research updates.

ASH

12/18/2025

Sequencing BTKi Therapies in Patients With CLL

Claudia Villa Celi, MDDaniel Ermann, MD

1. Two healthcare professionals, a male and female doctor, smiling against a city skyline at dusk, promoting oncology research updates on BTK inhibitors and therapy in CLL.

ASH

12/17/2025

SEQUOIA Trial Long-Term Data Support Second-Generation BTK Inhibitors in CLL

Catherine Coombs, MDDaniel Ermann, MD

Imaging for oncological research on follicular lymphoma, featuring MDs Urshila Durani and Joshua Brody, highlighting practice-changing data from EPCORE FL-1 clinical trial in a skyline cityscape background.

ASH

12/17/2025

Primary Results From EPCORE FL-1 Presented at ASH 2025

Urshila Durani, MD, MPHJoshua Brody, MD

1. New research data on lymphoma care presented at ASH 2025, emphasizing advances from frontline treatment to relapse management.

ASH

12/14/2025

New Data at ASH 2025 Reshapes Lymphoma Care From Frontline to Relapsed Disease

Rafaella Litvin, MD

EHA

View All

Panel of three medical professionals at EHA 2026 conference discussing leukemia and myelofibrosis presentations.

EHA

08/03/2026

Key Leukemia and Myelofibrosis Presentations at EHA 2026

Eunice Wang, MDRahul Gosain, MD, MBARohit Gosain, MD

Group photo of three medical professionals discussing lymphoma presentations at EHA 2026.

EHA

07/31/2026

4 Key Lymphoma Presentations From EHA 2026

Carla Casulo, MDRahul Gosain, MD, MBARohit Gosain, MD

Two doctors, Dr. Rahul Banerjee and Dr. Rohit Gosain, featured in a digital graphic about emerging data for CELMoDs in multiple myeloma.

EHA

07/22/2026

The Emerging Data for CELMoDs in Multiple Myeloma

Rahul Banerjee, MD, FACPRohit Gosain, MD

Dr. Rahul Banerjee, Dr. Rohit Gosain, and Dr. Rahul Gosain discuss key updates from EHA 2026 on multiple myeloma trials.

EHA

07/07/2026

5 Key Multiple Myeloma Trial Updates From EHA 2026

Rohit Gosain, MDRahul Gosain, MD, MBARahul Banerjee, MD, FACP

ESMO

View All

Key updates from ESMO Breast Cancer 2026, featuring Dr. Rahul Gosain, Dr. Rohit Gosain, and Dr. Erika Hamilton discussing recent advances in breast cancer trials.

ESMO

05/29/2026

Six Major Trial Updates From ESMO Breast Cancer 2026

Erika Hamilton, MD, FASCORahul Gosain, MD, MBARohit Gosain, MD

1. Medical professional analyzing lung cancer CT scan highlighting tumor with red laser pointer, illustrating cancer diagnosis and screening.

ESMO

11/25/2025

Revolutionizing Treatment for EGFR-Mutated NSCLC

Coral Olazagasti, MD

ESMO 2025 conference banner highlighting updates in HR+ metastatic breast cancer landscape, with a historic building in the background.

ESMO

11/10/2025

ESMO 2025: Updates in the HR+ Metastatic Breast Cancer Landscape

Sarah Premji, MDKarthik Giridhar, MD

Advanced medical professionals discussing lung cancer updates at ESMO 2025 conference, emphasizing recent oncological research and treatment innovations for thoracic oncology.

ESMO

11/07/2025

5 Updates From ESMO 2025 for Lung Cancer Oncologists

Rami Manochakian, MDRohit Gosain, MDRahul Gosain, MD, MBA

PSA test blood sample for prostate cancer detection in laboratory setting.

ESMO

11/06/2025

ESMO 2025 Updates in Prostate Cancer: Advances in Radioligand, Genomic, and AR-Targeted Therapies

Michael Serzan, MD

ESMO 2025: SERDs, mTOR inhibitors, and VIKTORIA-1 targeted therapies for advanced breast cancer research and treatment advancements.

ESMO

11/05/2025

Metastatic Breast Cancer Updates: SERDs, mTOR Inhibitors, and VIKTORIA-1

Erika Hamilton, MD, FASCOSarah Premji, MD

Advanced medical conference featuring Dr. Rachna Shroff, Dr. Rohit Gosain, and Dr. Rahul Gosain discussing key updates on gastrointestinal cancer from ESMO 2025 in a professional setting.

ESMO

11/04/2025

5 Key GI Cancer Updates From ESMO 2025

Rachna Shroff, MD, MS, FASCORohit Gosain, MDRahul Gosain, MD, MBA

8 Practice-Changing Breast Cancer Presentations From ESMO 2025 with leading doctors Dr. Rahul Gosain, Dr. Rohit Gosain, and Dr. Virginia Kaklamani; innovative updates in breast cancer diagnosis, treatment, and care discussed at OncUpdates.

ESMO

11/03/2025

8 Practice-Changing Breast Cancer Presentations From ESMO 2025

Virginia Kaklamani, MD, DScRahul Gosain, MD, MBARohit Gosain, MD

Updated Results from monarchE Presented at ESMO 2025, featuring Erika Hamilton, MD, FASCO, and Sarah Premji, MD, discussing recent oncology advancements.

ESMO

10/31/2025

Dr. Erika Hamilton on Updated Results From monarchE Presented at ESMO 2025

Erika Hamilton, MD, FASCOSarah Premji, MD

Advanced oncology conference presentation featuring Dr. Rahul Gosain, Dr. Rohit Gosain, and Dr. Stephanie Berg discussing top GU oncology topics from ESMO Congress 2025.

ESMO

10/30/2025

Top 5 GU Oncology Presentations From ESMO Congress 2025

Stephanie Berg, DORahul Gosain, MD, MBARohit Gosain, MD

Berlin Museum Island with historical architecture and river view during sunset, featuring a boat cruising on the Spree River, with modern Berlin skyline in the background.

ESMO

10/29/2025

ESMO 2025: Updates in Bladder Cancer

Vishesh Khanna, MD

Electronic health records consultation with healthcare professional discussing cancer treatment options.

ESMO

10/28/2025

ESMO 2025 Breaking New Ground in Breast Cancer: Five Trials to Know

Matthew Kurian, MD

Vibrant scientific laboratory scene with test tubes and a pipette, showcasing advanced cancer research and clinical trials, highlighting oncology innovations and medical breakthroughs in cancer treatment.

ESMO

10/25/2025

ESMO 2025: Updated Results From the monarchE Trial in Early Breast Cancer

Sarah Premji, MDMatthew Goetz, MD

Microscopic view of cancer cells, illustrating cellular structures and tumor development for oncology research and cancer treatment insights.

ESMO

10/24/2025

Key Updates in Gastrointestinal Oncology from ESMO 2025

Udhayvir Singh Grewal, MD

Berlin cityscape at dusk with the TV Tower, historic buildings, and river, highlighting oncology research and medical innovation in Germany for oncology updates and cancer treatment advancements.

ESMO

10/17/2025

The 12 Most Anticipated Practice-Changing Abstracts at ESMO 2025: Community Oncologist’s Guide

Sawyer Bawek, DO

SABCS

View All

Dr. Rebecca Shatsky discusses clinical trials on adjuvant carboplatin and PARP inhibitors in triple-negative breast cancer (TNBC) at OncUpdates.

SABCS

03/05/2026

Adjuvant Carboplatin and PARP Inhibitor Combination Trials in TNBC

Rebecca Shatsky, MDRahul Gosain, MD, MBARohit Gosain, MD

Dr. Harold Burstein presenting at SABCS 2025 on four key HER2+ breast cancer trials, with images of Dr. Rahul Gosain and Dr. Rohit Gosain in the background.

SABCS

02/10/2026

4 Significant Trials for HER2+ Breast Cancer at SABCS 2025

Harold Burstein, MD, PhDRohit Gosain, MDRahul Gosain, MD, MBA

Early morning view of a waterfront with a promotional banner for OncUpdates, featuring Dr. Hope Rugo and two other doctors discussing metastatic HR+ breast cancer highlights for SABCS 2025.

SABCS

02/06/2026

HR+ Metastatic Breast Cancer Updates from SABCS 2025

Hope Rugo, MD, FASCORahul Gosain, MD, MBARohit Gosain, MD

1. Hands holding a pink ribbon symbolizing breast cancer awareness on a gray background.

SABCS

01/17/2026

From ADCs to Oral SERDs: Practice-Changing Insights from SABCS 2025

Zunairah Shah, MD

1. Expert doctors Mariam Haji Ahmad and Alexis Levee discuss early use of first-line ADCs in breast cancer treatment and advancements in sequencing technology for improved patient outcomes.

SABCS

01/17/2026

Impact of ADCs in Early TNBC Treatment

Mariam Haji Ahmad, MBBChAlexis Levee, MD

Antibody-drug conjugates reshaping triple-negative breast cancer treatment algorithm, oncologists discuss advances.

SABCS

01/15/2026

ADCs in TNBC: Current Data and Unanswered Questions

Pietro De Placido, MDDionisia Quiroga, DO, PhD

Inovative breast cancer research and treatment insights from OncUpdates, featuring experts Tyler Kristoff, MD, and Sarah Premji, MD, focusing on the role of Inavolisib as a first-line therapy and emerging oral SERDs.

SABCS

01/13/2026

SABCS 2025 Updates on Inavolisib and Giredestrant in Breast Cancer

Tyler Kristoff, MDSarah Premji, MD

1. In-depth analysis of HR+ and early breast cancer studies from SABCS 2025 featuring experts Dr. Rohit Gosain, Dr. Rahul Gosain, and Dr. Laura Huppert.

SABCS

01/12/2026

Key HR+, Early Breast Cancer Abstracts From SABCS 2025

Laura Huppert, MDRahul Gosain, MD, MBARohit Gosain, MD

HER2-positive breast cancer research update featuring Yash Agrawal, MD, and Stephanie Graff, MD, discussing 2025 advancements in DESTINY trials and beyond for improved breast cancer therapies.

SABCS

01/05/2026

The Evolving Role of T-DXd Across HER2+ Breast Cancer

Yash Agrawal, MDStephanie Graff, MD, FACP, FASCO

1. Female healthcare professionals discussing breast cancer prevention and patient advocacy for cancer care education and empowerment.

SABCS

01/04/2026

Patient Advocacy Brings Breast Cancer Vaccine to Phase 1 Trial

Judy FitzgeraldKarissa Britten, MD

Enhanced image of two medical professionals discussing CDK4/6 inhibitors for cancer treatment at OncUpdates, with a cityscape background highlighting expertise in oncology research and therapy options.

SABCS

01/02/2026

NATALEE 5-Year IDFS Data at SABCS 2025

Matthew Kurian, MDJasmin Hundal, MD

1. Expert discussion on TROP2 ADC options in PD-L1-negative TNBC featuring Alexis LeVee and Paolo Tarantino, MD.

SABCS

01/01/2026

Anti-TROP-2 ADCs in PD-L1-Negative TNBC

Alexis Levee, MDPaolo Tarantino, MD

1. Advanced biomarker-guided care in HER2-positive breast cancer using ctDNA, TILs, and HER2DX for personalized oncology treatment and improved patient outcomes.

SABCS

12/31/2025

Emerging Roles of Biomarkers in HER2-Positive Breast Cancer

Yash Agrawal, MDMadison Canning, MD

HER2-positive breast cancer updates from SABCS 2023, featuring expert Vaishali Deenadayalan at Roswell Park, emphasizing advancements in treatment and research in oncology for improved patient outcomes.

SABCS

12/30/2025

Updates in HER2-Positive Breast Cancer From SABCS 2025

Vaishali Deenadayalan, MD

1. Interpreting MONALEESA, NATALEE, and monarchE in clinical oncology practice, featuring healthcare professionals discussing advanced breast cancer treatments.

SABCS

12/29/2025

SABCS 2025: Expert Perspective on CDK4/6 Inhibitor Use in Metastatic Hormone Receptor-Positive Breast Cancer

Matthew Kurian, MDElia Segui Solis, MD

1. Advanced breast cancer treatment strategies for early HER2-positive cases, featuring expert insights from MDs Ya Haddy Salah and Nerea Lopetegui.

SABCS

12/28/2025

De-escalation and Sequencing Strategies Shape HER2-Positive Breast Cancer Care at SABCS 2025

Nerea Lopetegui-Lia, MDYa Haddy Sallah, MD, MPH

Innovative hormone receptor-positive breast cancer treatment paradigms discussed by Dr. Jasmin Hundal, expert from Cleveland Clinic, highlighting advancements and research updates in oncology.

SABCS

12/27/2025

Shifting Treatment Paradigms in Hormone Receptor–Positive Breast Cancer

Jasmin Hundal, MD

1. Integrating Tucatinib and T-DXd for HER2-positive breast cancer treatment, across disease settings, to enhance targeted therapy effectiveness and patient outcomes.

SABCS

12/26/2025

SABCS 2025: HER2CLIMB-05 and DESTINY Trials Point to More Individualized Care in HER2-Positive Breast Cancer

Nerea Lopetegui-Lia, MDSusan Dent, BSc, MD

Accelerating breast cancer treatment research by integrating Sacituzumab govitecan, Pembrolizumab, with expert clinicians Dionisia Quiroga, DO, PhD, and Erika Hamilton, MD, in Las Vegas skyline background.

SABCS

12/25/2025

SABCS 2025: Clarifying Where Sacituzumab Govitecan Fits in the Breast Cancer Treatment Landscape

Erika Hamilton, MD, FASCODionisia Quiroga, DO, PhD

Adjuvant CDK4/6 inhibition in early breast cancer discussed by renowned experts Matthew Kurian and Komal Jhaveri at OncUpdates.

SABCS

12/21/2025

NATALEE and Other Updates for HR+ Early Breast Cancer at SABCS 2025

Komal Jhaveri, MD, FACPMatthew Kurian, MD

SABCS

12/19/2025

Evolving Treatment Paradigms in Advanced Breast Cancer: Key Trial Updates From SABCS 2025

Karissa Britten, MDVaishali Deenadayalan, MD

1. Advances in early-stage breast cancer treatment focusing on CDK4/6 inhibitors for adjuvant therapy.

SABCS

12/19/2025

Key Insights From the NATALEE Trial

Karissa Britten, MDMatthew Kurian, MD

Advances in early-stage and metastatic triple-negative breast cancer (TNBC) treatments, featuring expert insights from Dr. Briana To, highlighting evolving oncologic approaches and clinical research.

SABCS

12/19/2025

Evolving Approaches to Early-Stage and Metastatic TNBC

Briana To, DO, PhD

1. AlT text: Expert discussion on managing breast cancer relapse with adjuvant CDK4/6 inhibitor therapy in ER-positive cases, featuring Dr. Sarah Premji and Dr. Kevin Kalinsky.

SABCS

12/18/2025

SABCS 2025: Evolving Role of CDK4/6 Inhibitors and SERDs in ER-Positive Breast Cancer

Kevin Kalinsky, MD, MS, FASCOSarah Premji, MD

Innovative medical conference with healthcare professionals discussing oncology treatments and latest cancer research advancements in a modern venue.

SABCS

05/23/2025

Advances in Managing CNS Metastases in Breast Cancer: SABCS 2024 Insights

Hetal Mistry, MD

WCLC

View All

Malignant tumor in the lung with cancerous growth and tumor cells, medical illustration of lung cancer pathology for oncology and cancer research.

WCLC

11/17/2025

Dual Targeting: Iza-bren Shows Promising Early Results Across Solid Tumors

Samantha El Warrak, MBBSChinmay Jani, MD

Lung cancer with tumor showing cancerous growth affecting the bronchi and surrounding lung tissue, emphasizing medical research and oncology treatment.

WCLC

11/14/2025

PALOMA-2: Subcutaneous Amivantamab Plus Lazertinib Delivers MARIPOSA-Level Efficacy with Improved Safety

Akshee Batra, MDChinmay Jani, MD

Innovative targeted antibody-drug conjugate for relapsed small cell lung cancer (SCLC) at WCLC 2025. Focus on recent developments in cancer immunotherapy and targeted treatments for lung cancer patients.

WCLC

11/13/2025

DLL3-Targeted Antibody-Drug Conjugate Reignites Hope for Relapsed SCLC

Asad Rauf, MDChinmay Jani, MDAman Chauhan, MD

CT scan of a chest showing lung health, used in cancer diagnosis and treatment monitoring.

WCLC

11/12/2025

Chemotherapy Plus Osimertinib Offers Overall Survival Benefit in EGFR-mutated NSCLC

Daniel Tuerff, MDChinmay Jani, MDEstelamari Rodriguez, MD, MPH

WCLC 2025 oncology conference highlights featuring key researchers discussing FLURA2, HARMONI, and ALCHEMIST targeted therapies for lung cancer treatment.

WCLC

10/08/2025

Key NSCLC Trials From WCLC 2025

Balazs Halmos, MDRahul Gosain, MD, MBARohit Gosain, MD